Posts Tagged ‘Financing’

Inotek May Be for Sale, But Who Will Buy?

Inotek May Be for Sale, But Who Will Buy?

With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding a buyer could be difficult. The dominoes started to fall in January, when Inotek reported that the trial of monotherapy trabodenoson did not achieve the results it was looking for.…

Read More

Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

With the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar into rarified air, reaching an all-time high above $55, about 38% higher than before the announcement – and even those pre-announcement prices were in record territory for the stock. If…

Read More

Roche/Genentech’s Second Move to Protect Lucentis Franchise

With its patents on Lucentis set to expire in a few years and clinical trials of at least three Lucentis biosimilars underway, Roche’s recent acquisition of ForSight VISION4 is seen by many as the latest strategic move to protect its Lucentis franchise for the foreseeable future. The ForSight VISION4 acquisition gives Roche and its subsidiary,…

Read More

Eye on Five – January Edition

OIS-Eye-On-Five

Alcon Turnaround Has Novartis Exploring Spin-off With its Alcon turnaround plans on track, Novartis AG revealed it is exploring options that include spinning off Alcon or issuing an IPO for the eye-care unit – or even keeping it. Alcon lost $120 million in fourth-quarter 2016 and $132 million for the year versus a profit of…

Read More

After Stunning Phase III Results, Ophthotech Seeks a Path Forward

Eye On Innovation Article - After stunning Phase 3 results, Ophthotech seeks a path forward - Healthegy

After disappointing Phase III results of Fovista (pegpleranib) in combination with Lucentis (ranibizumab, Genentech) sent its stock reeling, Ophthotech Corporation is reevaluating not only the trial data but also how the results will impact ongoing Fovista combination trials as well as its overall business. And while Ophthotech may have the equivalent of financial pneumonia, if…

Read More

Eye on Five – November Edition

OIS - Eye on Five

Trump Bump Fuels Biotech, Pharma Stocks Pharma and biotech stocks surged in the week after Donald Trump’s election, with the OIS Index jumping 13% and the NASDAQ Biotech Index surging 11.2%. The gains have since trailed off, but the latter index was still up 8% for November at month-end. Three anticipated policy changes have fueled…

Read More

Diagnostics Here to Stay

A panel of physicians and corporate leaders discuss the increasingly important impact diagnostics have on the premium channel. Topics included number of tests done, appetite of investors and interest of corporate partners. Video Highlights 00:20 How important are preoperative diagnostics in managing the premium channel. 00:29 – Jay Pepose, MD, PhD, It’s very important. If…

Read More

CEO John Hendrick on Zepto’s Fast Development

Mynosys Cellular Devices is developing Zepto, a disposable device, used in cataract surgery that uses precision pulse technology. The company notes the device is accurate and creates a reproducible capsulotomy that is quick, safe, and affordable. Zepto consists of a silicon suction cup, a nitinol capsulotomy cutting element and an incision finder/push-rod system. Highlights 01:00…

Read More

Ivantis Goes After Canal-based MIGS

Ivantis was founded in 2007 by two coronary stent inventors to develop “the only minimally invasive microstent for glaucoma that dilates and scaffolds Schlemm’s canal.” With 25 full-time employees, the company has raised $102 million, and closed a $71 million B round last year, said Dave van Meter, president and CEO. More than 2,500 patients…

Read More

Encore Vision Reports Positive Phase I/II Results

Results from a Phase I/Phase II study of EV06 ophthalmic solution for the treatment of presbyopia show “it works to restore bilateral near vision. It is safe and well-tolerated,” said president and CEO Bill Burns. Encore Vision has just come off a round of successful capital financing that should see it through the next phase…

Read More

InnFocus’ Trenary Discusses New Funding, Timeline

To watch InnFocus’ OIS Companies to Watch Presentaion Click Here InnFocus CEO Russ Trenary participated in our Glaucoma section of OIS@ASCRS. We caught up with him in the hallways to discuss his company’s success. He’s also been a guest on our OIS Podcast. Video Highlights: 00:30 – How much did InnFocus raise and who were…

Read More

Graybug Vision – Flush with Cash – Is Making Big Moves to Change its Approach to Finding New Treatments for Wet AMD & Other Eye Disease

Graybug Vision – Flush with Cash – Is Making Big Moves to Change Its Approach to Finding New Treatments for Wet AMD and Other Eye Disease - OIS Podcast

Graybug interim CEO Jeff Cleland shares details on the company’s $44.5 million Series B. Cleland gives a report on investor appetite for ophthalmology companies. He also explains how the firm would use the capital to shift its approach from a drug delivery platform technology company to a drug maker. Ten Top Topics in this OIS…

Read More